Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.75 |
| ▸ | RAB9A | P51151 | 6/20 | 0.75 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.62 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMO | Q99835 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3771110 | 0.87 | NPC1 (0.63) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3771629 | 0.87 | NPC1 (0.66) | NPC1RAB9AKCNK3KCNK9MEN1 | |
| SCHEMBL3771069 | 0.87 | NPC1 (0.78) | NPC1RAB9AKCNK3KCNK9MEN1 | |
| SCHEMBL3764441 | 0.87 | RAB9A (0.78) | NPC1RAB9AKCNK3KCNK9MAPT | |
| SCHEMBL23657654 | 0.87 | NPC1 (1.00) | NPC1RAB9AKMT2A | |
| SCHEMBL3771639 | 0.86 | NPC1 (0.75) | NPC1RAB9APTGESMEN1KMT2A | |
| SCHEMBL3772942 | 0.86 | KCNK3 (0.62) | NPC1RAB9AKCNK3KCNK9MEN1 | |
| SCHEMBL3770483 | 0.86 | KMT2A (0.62) | NPC1RAB9APTGESMAPTMEN1 | |
| SCHEMBL3771572 | 0.86 | NPC1 (0.59) | NPC1RAB9APTGESMEN1KMT2A | |
| SCHEMBL3769427 | 0.84 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| WO-2009103778-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2009-08-27 | — | — | WO | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | NPC1 145/4885RAB9A 2083/4885PTGES 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.